The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 685K Compounds and 4.6K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

19 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Isozyme-specific enzyme inhibitors. 11. L-homocysteine-ATP S-C5' covalent adducts as inhibitors of rat methionine adenosyltransferases.EBI
TBA
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.EBI
TBA
Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors.EBI
Hubei Bio-Pharmaceutical Industrial Technological Institute
Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability.EBI
Guizhou University
Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening.EBI
Orion Pharma
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.EBI
Agios Pharmaceuticals
Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.EBI
China Pharmaceutical University
Fragment-Based Design of a Potent MAT2a Inhibitor and EBI
Astrazeneca
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous EBI
Agios Pharmaceuticals
Methionine Adenosyltransferase Inhibitors for the Treatment of Cancer.EBI
Usona Institute
Exploiting binding-site arginines in drug design: Recent examples.EBI
Prelude Therapeutics
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.EBI
TBA
COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAMEBDB
Chong Kun Dang Pharmaceutical
IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASEBDB
Biogen Ma
5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOFBDB
Origiant Pharmaceutical
Benzimidazoles and indoles as taro inhibitorsBDB
Merck Sharp & Dohme
Heterocyclic derivatives as PI3K inhibitorsBDB
Incyte
Piperidines as covalent menin inhibitorsBDB
The Regents of The University of Michigan
Compositions useful for treating disorders related to kitBDB
Blueprint Medicines